Siegfried Holding AG represents a set of core values and corporate philosophy that guides its operations. The company focuses on innovation, quality, and sustainability to continuously develop and manufacture sophisticated drug substances and drug products for the pharmaceutical industry. With a dedication to excellence, Siegfried Holding AG prioritizes customer satisfaction and strives to deliver high-quality solutions that meet the highest standards. Through collaborative partnerships, the company aims to provide value-added services to its clients and build long-term relationships. By embracing a responsible approach, Siegfried Holding AG contributes to a healthier and more sustainable future in the pharmaceutical sector.

Siegfried Holding AG is primarily present in Switzerland, Germany, France, Malta, China, and the United States.

Siegfried Holding AG has achieved several significant milestones throughout its history. One of the key milestones was the company's successful IPO in 1997, which enabled it to expand its operations and enhance its global presence. Another important achievement was Siegfried Holding AG's acquisition of Hameln Pharmaceuticals in 2014, which fortified its position in the market and broadened its product portfolio. Furthermore, the company's continuous focus on research and development has led to the successful development and launch of various innovative pharmaceutical products. Siegfried Holding AG's commitment to sustainability and high-quality manufacturing practices has also been recognized through certifications such as ISO 9001 and ISO 14001.

Siegfried Holding AG is a renowned pharmaceutical company that has a rich history and a strong background. Founded in 1873, the company has been operating for over 145 years. Originally established as a chemical dye manufacturer, Siegfried transitioned into the pharmaceutical sector in the early 20th century and has since become a leading global player in contract development and manufacturing. Specializing in the production of highly complex pharmaceutical substances, the company prides itself on its state-of-the-art facilities, extensive expertise, and commitment to innovation. Siegfried Holding AG has built a solid reputation for consistently delivering high-quality products and services to its diverse customer base worldwide.

The main competitors of Siegfried Holding AG in the market include companies like Lonza Group AG, Siegfried Ltd., Catalent Inc., Johnson Matthey Plc, and Patheon N.V.

Siegfried Holding AG is primarily active in the pharmaceutical and chemical industries.

The business model of Siegfried Holding AG revolves around providing life science clients with custom development and manufacturing solutions. As a leading contract development and manufacturing organization (CDMO), Siegfried Holding AG offers a comprehensive range of services, including formulation development, clinical and commercial manufacturing, packaging, and supply chain management. The company's expertise lies in complex molecules and sterile drug products, enabling it to support clients throughout the entire product life cycle, from early-stage development to commercial production. Siegfried Holding AG's commitment to quality, innovation, and customer satisfaction has made it a trusted partner in the pharmaceutical and biotech industries worldwide.

Siegfried Holding의 P/E 비율은 22.29입니다.

Siegfried Holding의 P/S 비율은 2.73입니다.

Siegfried Holding에 대한 AlleAktien 품질 점수는 9/10입니다.

예상되는 Siegfried Holding 매출은 1.39 조. CHF입니다.

예상되는 Siegfried Holding 이익은 170.29 백만 CHF입니다.

The Siegfried Holding AG is a publicly traded Swiss company specializing in the development, production, and marketing of pharmaceuticals, active ingredients, and chemicals. The company is divided into three main business segments: Pharma Services, Drug Products, and API. In the Pharma Services segment, Siegfried offers a comprehensive range of services for customers in the pharmaceutical and biotech industries, including the development and optimization of production processes, analysis of active ingredients, and production of clinical trial batches. Additionally, the Pharma Services segment also provides contract research services, ranging from identification to the optimization and production of active ingredients. In the Drug Products segment, the company manufactures finished pharmaceutical products for third-party companies. The product range includes both generics and specialty products. The goal of this business segment is to meet the needs of customers worldwide by producing high-quality pharmaceuticals. Siegfried's product range includes tablets, capsules, injectable preparations, and dry syrups. As a significant manufacturer of pharmaceutical active ingredients in Europe, Siegfried also has extensive experience in the production of APIs. The API segment produces pharmaceutical active ingredients based on customer requirements. Siegfried's long-standing experience in the production and analysis of active ingredients and finished products ensures the highest quality standards for active ingredients. Another highlight of Siegfried is its specialty chemicals derived from industries outside of the pharmaceutical business. Siegfried's comprehensive expertise in organic chemistry, polymer chemistry, and contract manufacturing is particularly important in this regard. Siegfried also offers specialized solutions in the reprocessing of specialty chemicals and provides tailored services based on this expertise. Siegfried focuses on partnerships and strategic acquisitions. The company operates locations worldwide, covering the entire supply chain. Both organic growth strategies and strategic acquisitions are implemented to meet customer needs and expand the company's competencies. Overall, Siegfried offers its customers services and products of the highest quality, making it an interesting option for companies looking for a reliable partner in the fields of pharmacy, specialty chemistry, or contract manufacturing. The diverse business segments make Siegfried an important player in the pharmaceutical industry and demonstrate the company's high potential.

Siegfried Holding은(는) 연간 1번의 배당을 통해 0.32 CHF의 배당금을 지급합니다.

Siegfried Holding는 연간 1번의 배당금을 지급합니다.

Siegfried Holding의 ISIN은 CH0014284498입니다.

Siegfried Holding의 WKN은 891169입니다.

Siegfried Holding의 티커는 SFZN.SW입니다.

지난 12개월 동안 Siegfried Holding은(는) 3.6 CHF 의 배당금을 지급했습니다. 이는 약 4.09 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Siegfried Holding은(는) 0.59 CHF의 배당금을 지급할 것으로 예상됩니다.

Siegfried Holding의 현재 배당 수익률은 4.09 %입니다.

Siegfried Holding은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Siegfried Holding은(는) 지난 8년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0.59 CHF의 배당금이 예상됩니다. 이는 배당수익률 0.67 %에 해당합니다.

Siegfried Holding은 '건강' 섹터에 속합니다.

Siegfried Holding의 마지막 배당금을 3.8 CHF만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Siegfried Holding는 3.4 CHF를 배당금으로 지급했습니다.

Siegfried Holding의 배당금은 CHF에 지급됩니다.